^
Association details:
| Biomarker: | CD20 overexpression |
|---|---|
| Cancer: | Peripheral T-cell Lymphoma |
| Regimen: | CVAD (vincristine + dexamethasone injection + doxorubicin hydrochloride + cyclophosphamide) |
| Direction: | Resistant |
Evidence:
Source:
Title:
T-cell lymphoma with abundant CD20 expression showing a good response to rituximab with gemcitabine, oxiplatin, and L-asparaginase (R-pGEMOX): A case report
Excerpt:
A 65-year-old man was diagnosed with T-cell lymphoma with abundant CD20 expression. He was refractory to cyclophosphamide + epirubicin + vincristine + prednisone + etoposide (CHOPE), ifosfamide + cisplatin + etoposide + dexamethasone (DICE), and hyper-cyclophosphamide + vincristine + epirubicin + dexamethasone (CVAD) chemotherapy.
DOI:
10.1097/MD.0000000000010199.
